iTeos Therapeutics
Belgium-based iTeos Therapeutics develops immunomodulators and medical devices for cancer treatment.
Founded
2011Belgium-based iTeos Therapeutics develops immunomodulators and medical devices for cancer treatment.
Founded in Belgium, iTeos Therapeutics is a biotechnology company specializing in the development of immunomodulators and medical devices for cancer treatment. The company's core mission is to leverage its deep understanding of tumor immunology to create highly differentiated immuno-oncology therapeutics, particularly targeting lung, pancreatic, and liver cancers. iTeos focuses on designing novel product candidates that improve the clinical benefits of oncology therapies, aiming to provide targeted immunotherapies for cancer patients.
Notable affiliated individuals and investors include prominent figures in the biotech industry and leading venture capital firms. iTeos has achieved significant milestones, including advancing its product candidates into clinical trials and establishing a robust pipeline of innovative cancer therapies. The company's impact is marked by its commitment to pioneering new treatments that address unmet needs in oncology, thereby contributing to the advancement of cancer immunotherapy.
Companies similar to iTeos Therapeutics include Xios Therapeutics, AIM Immunotech, Immune-Onc Therapeutics and Immunome.
iTeos Therapeutics was founded in 2011.
iTeos Therapeutics' headquarters is located in Watertown, MA, US.
iTeos Therapeutics' most recent funding round was for $125M (USD) in April 2020.
As of Apr 1, 2020, iTeos Therapeutics has disclosed funding of $249.8M (USD). Undisclosed round amounts are excluded.
iTeos Therapeutics has 125 employees as of Feb 6, 2024.
Immunome
